BIIB080 is an investigational tau-lowering antisense medicine. It is not an approved dementia treatment.
Biogen’s intrathecal ASO programme targets tau RNA. Phase 2 safety and cognition outcomes are still being established. Not for self-administration.
Investigational antisense oligonucleotide aimed at reducing MAPT / tau expression. Connects to Tau.
1.Diranersen (BIIB080) slips into a pocket on Tau.
Same-target crowding
Products and sponsors that share a biology node on this atlas. A crowded target is a duplication signal, not a recommendation.
Tau is the tangle protein. Its spread tracks symptoms more closely than plaques in many studies.
2 products · 2 sponsors
Products on this atlas
Linked trials
Counts are what this atlas records on one target — not a ranking of funders or clinical promise.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Diranersen" OR ABSTRACT:"Diranersen" OR TITLE:"BIIB080" OR ABSTRACT:"BIIB080") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Diranersen (BIIB080), not a curated reading list.
Shares Tau-directed therapeutics, Tau, Alzheimer’s disease and the tag dementia-atlas.
Shares Tau, Alzheimer’s disease and the tag dementia-atlas.
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
Shares Tau, Alzheimer’s disease and the tag dementia-atlas.
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
